A young bride's tragic story highlights a critical issue in healthcare. Natalie, a 31-year-old from Coventry, passed away just weeks after her wedding, succumbing to an aggressive brain tumour. But her legacy lives on through her mother's advocacy for better access to clinical trials.
Natalie's mother, Liz Paul, is supporting the Access to Clinical Trials for Brain Tumours (ACT-BT) initiative, which aims to improve the dire situation of brain tumour patients in the UK. Brain tumours are the leading cause of cancer deaths for those under 40, yet clinical trial participation is shockingly low. A mere 12% of brain tumour patients have taken part in trials, according to a report by The Brain Tumour Charity.
The reasons behind this are complex. But here's where it gets controversial: the report highlights limited awareness and geographical barriers as key issues. Less than half of those surveyed were informed about research opportunities, and the distance from specialist cancer centres affects trial accessibility. Additionally, the lack of support for patients' cognitive and physical well-being hinders their ability to participate.
Natalie's journey is a testament to these challenges. Diagnosed in 2017, she underwent numerous operations and grueling radiotherapy and chemotherapy sessions. Her family even raised funds for immunotherapy treatment in Germany, costing £56,000 per round, excluding travel. Despite their efforts, Natalie passed away in November 2021, only seven weeks after her wedding.
ACT-BT, a joint effort by The Brain Tumour Charity and the University of Leeds, aims to address these issues. It connects UK consultants with a panel of clinical trial experts who will review cases and match patients to suitable trials. This initiative promises to improve trial accessibility and gather data to advocate for more trials and resources.
The ACT-BT programme is set to launch in late spring, allowing medical consultants to refer adult patients with primary brain tumours to the panel via an online form. This streamlined process will provide prompt, personalized guidance, ensuring patients receive the best possible care. The panel, consisting of 10 experts, will meet weekly to review cases, with each member leading a national study and providing accurate trial information.
Professor Susan Short, ACT-BT lead, emphasizes the importance of removing barriers to clinical research. By improving access to trials, they aim to accelerate the discovery of new treatments. The Brain Tumour Charity is funding ACT-BT's initial eight-month pilot phase, including a coordinator post and members' time.
Dr. Michele Afif, Chief Executive at The Brain Tumour Charity, expressed pride in funding this initiative, acknowledging the slow progress in brain tumour research due to systemic barriers. By increasing trial participation, they hope to develop more effective treatments and give patients a better chance at longer, healthier lives.
ACT-BT will collaborate with international platforms like myTomorrows to boost trial participation and advocate for more resources. The charity also funds the Patient and Public Involvement and Engagement (PPIE) aspect, ensuring patient voices are central to the initiative. Dr. Helen Bulbeck, co-founder of brainstrust, stresses the importance of involving patients and caregivers to create a supportive system that truly meets their needs.
Natalie's story is a powerful reminder of the urgent need for improved brain tumour care. By supporting initiatives like ACT-BT, we can ensure that more patients have access to potentially life-saving treatments. But the question remains: Are we doing enough to address the systemic barriers in brain tumour research and care? Share your thoughts in the comments below.
